This just came down the art events pipeline:
The non-profit new media arts org in NYC, Eyebeam is hosting "Living Culture" as part of its Summer School and Digital Day Camp programs. From the website:
Living Culture is a screening program of short moving image works addressing the impact of genetics and biotechnology on art that will be presented at Eyebeam on Thursday July 27th at 7pm. The screening will complement work produced in the Summer School and Digital Day Camp programs presented in an exhibition devoted to similar themes.
The screening will include work from: Oron Catts, Gina Czarnecki, Gair Dunlop, Bradley Eros, Lorenzo Oggiano, Casey Reas, Paul Vanouse, Adam Zaretsky and Ionat Zurr.
A new project by an artist in British Columbia purports to discuss preimplantation genetic diagnosis. The artist plans on using a blog to archive comments and thoughts from interested participants that will then be used in an installation.
What is the relationship between spectacle and science, image and discourse? This question seems key in the aesthetic engagement of biotech.
Apparently, Venezuela's Chavez has announced a prohibition on transgenic crops, which would counter an earlier agreement between Venezuela and Monsanto.
While not surprising that Chavez would resist US pressures and interests regarding transgenic agriculture, it is a big shift in policy that could have interesting implications for US-South America relations, as they are tied up with agricultural economies.
As the oil industry deals with the dual realities of peak oil, both in terms of public perception and natural resources, it's no surprise that interest in the potential of biotech is on the rise. Biotech has already been marketed as a potential solution for oil spills, and now it seems companies like BP are looking for possible energy solutions, joining the Biotechnology Industry Organization. Meanwhile, other companies, like Shell, are taking an interesting position, arguing that the use of food for fuel should be avoided, making use of waste instead.
Earlier this month, the Guardian ran a story on the biotech firm Genentech and its licensing of a drug in such a manner that it's prohibiting its use as a cheap and effective treatment of blindness.
June 2004 July 2004 August 2004 September 2004 October 2004 November 2004 December 2004 January 2005 February 2005 March 2005 April 2005 May 2005 June 2005 July 2005 August 2005 September 2005 October 2005 November 2005 December 2005 January 2006 February 2006 March 2006 April 2006 May 2006 June 2006 July 2006 August 2006 September 2006 October 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 July 2007